Investment Thesis

Merck & Co., Inc. (MRK) is a BUY at current prices, primarily due to its strong position within the pharmaceutical industry and the continued growth potential of its product pipeline. The market appears to undervalue MRK's robust portfolio of innovative therapies and vaccines, especially as the company is strategically positioned to capitalize on increasing global healthcare needs. Given its stable revenue generation and strategic partnerships, MRK is likely to outperform its peers in the near term.

Competitive Moat

driven by its strong portfolio of intangible assets, particularly its intellectual property surrounding high-demand pharmaceuticals and vaccines. The durability of this moat is reinforced by the company's commitment to R&D, allowing it to maintain a pipeline of innovative products that sets it apart from competitors. However, competitive threats from generic drug manufacturers and emerging biotech companies could challenge Merck's market share, particularly in the oncology and virology sectors.

Growth Engine

Merck's future revenue growth is expected to stem primarily from its expanding oncology portfolio, particularly the continued success of its blockbuster drug, Keytruda, along with new launches in immunology and vaccines. The total addressable market (TAM) for oncology alone is projected to exceed $200 billion globally by 2027, providing a substantial revenue opportunity. Furthermore, geographic expansion into emerging markets is anticipated to enhance growth, with MRK gaining market share in regions with increasing healthcare expenditures. The focus on organic growth via R&D, along with selective acquisitions, positions Merck for sustained revenue increases.